Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
you are here: HomeNewsLupin
lupin
Jump to
  • Lupin gets tentative USFDA nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tablets Jan 31, 2023 12:49 PM IST

    Lupin gets tentative USFDA nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tablets

    The tentative approval by the United States Food and Drug Administration (USFDA) has been granted under the President's emergency plan for AIDS relief (PEPFAR), Lupin said in a regulatory filing.

  • Lupin recalls over 16,000 bottles of generic tuberculosis drug in US Jan 21, 2023 12:37 PM IST

    Lupin recalls over 16,000 bottles of generic tuberculosis drug in US

    The company initiated Class II nationwide (US) recall of the affected lot on December 12 last year.

  • Lupin launches combination drug for patients with heart failure conditions Jan 18, 2023 04:13 PM IST

    Lupin launches combination drug for patients with heart failure conditions

    The company said it has introduced Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg, in India.

  • Lupin gets USFDA nod for generic drugs to treat HIV infection Jan 16, 2023 01:53 PM IST

    Lupin gets USFDA nod for generic drugs to treat HIV infection

    The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in a regulatory filing.

  • Lupin gets US FDA nod for generic medicine to treat heart ailments Jan 10, 2023 04:07 PM IST

    Lupin gets US FDA nod for generic medicine to treat heart ailments

    These are the generic equivalent of Effient tablets, 5 mg and 10 mg of Cosette Pharmaceuticals, Inc.

  • Lupin trades higher on USFDA nod for generic bladder drug Jan 09, 2023 11:47 AM IST

    Lupin trades higher on USFDA nod for generic bladder drug

    Lupin Pharmaceutical got the United States' drug regulator's nod to market fesoterodine fumarate extended-release tablets

  • Stock Market LIVE: Buy or sell tech shares ahead of TCS result? IDBI Bank, Titan, Tata Steel in focus Jan 09, 2023 08:37 AM IST

    Stock Market LIVE: Buy or sell tech shares ahead of TCS result? IDBI Bank, Titan, Tata Steel in focus

    TCS to kick-off Q3 earnings season; how will IT stocks react in results week? Emirates NBD & Fairfax Group likely to have submitted expression of interest (EoI) for IDBI Bank stake: Moneycontrol Exclusive. Other stocks in focus: Titan, Tata Steel & Lupin.

  • Lupin launches triple drug combination to treat inadequately controlled asthma Jan 05, 2023 01:53 PM IST

    Lupin launches triple drug combination to treat inadequately controlled asthma

    The product will help by improving lung function, providing better symptom control and reducing exacerbations.

  • Stock Market Live: Will A Strong US Labour Market Drag World Markets Down ? Dec 23, 2022 09:06 AM IST

    Stock Market Live: Will A Strong US Labour Market Drag World Markets Down ?

    With the US labour market showing no signs of cooling off yet, and a tight labour market a major challenge for the US Fed, the worry that rates may stay high for a while have got markets jittery. Also on the show - Santo’s thoughts on Railtel Corp, Ingeroll Rand, Rail Vikas Nigam & Lupin.

  • Hot Stocks | Why you should bet on Lupin and TVS Motor, and sell Indian Hotels for short term Dec 23, 2022 07:08 AM IST

    Hot Stocks | Why you should bet on Lupin and TVS Motor, and sell Indian Hotels for short term

    Lupin has been overall moving in a rising channel and recently taken support near to Rs 720 zone which is also its 50 DEMA. It formed a bullish candle along with a decisive hold Rs 760 zone.

  • Stock Market Live: Diagnostics Stocks Back In Limelight Amid Covid Fears. Can The Momentum Sustain? Dec 22, 2022 08:53 AM IST

    Stock Market Live: Diagnostics Stocks Back In Limelight Amid Covid Fears. Can The Momentum Sustain?

    Diagnostics stocks saw a smart surge amid renewed fears of Covid outbreaks globally. Shares of Dr Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostic Centre and Thyrocare rallied up to 6% in yesterday as investors see brighter prospects for diagnostics and healthcare businesses amid Covid scare. Catch Santosh Nair's thoughts on whether this rally will sustain and also catch his views on Sula Vineyards which makes its debut on the stock exchanges today and Lupin.

  • Lupin launches generic joint pain drug in US market Dec 09, 2022 02:09 PM IST

    Lupin launches generic joint pain drug in US market

    The company's product -- Diclofenac Sodium Topical Solution 2 per cent -- is the generic version of Horizon Pharma Therapeutics Pennsaid, Lupin said in a statement.

  • Lupin appoints Spiro Gavaris as president of US generics business Dec 08, 2022 07:28 PM IST

    Lupin appoints Spiro Gavaris as president of US generics business

    Spiro, who had most recently served as president of Specialty Generics business at Mallinckrodt Pharmaceuticals and the president of US Injectables at Hikma, will be responsible for the overall strategy, implementation and growth of Lupin's US generics business

  • Lupin gets USFDA nod for generic medication Dec 05, 2022 04:05 PM IST

    Lupin gets USFDA nod for generic medication

    As per IQVIA data, Rufinamide tablets had estimated annual sales of USD 138 million in the US.

  • Stock Market Live: Why Are RVNL, IRCTC & Other Railway Cos' Shares Rising? | Paytm & Lupin In Focus Nov 29, 2022 08:23 AM IST

    Stock Market Live: Why Are RVNL, IRCTC & Other Railway Cos' Shares Rising? | Paytm & Lupin In Focus

    European markets were muted on Friday to close out an upbeat week, as the US Federal Reserve’s latest meeting minutes added to expectations that monetary policy tightening may slow down. As Nifty scales to record highs, we tell you how to make the most of your investments. On the technical front, we spotlight Paytm, Lupin.

  • Buy Lupin; target of Rs 855: Sharekhan Nov 28, 2022 06:49 PM IST

    Buy Lupin; target of Rs 855: Sharekhan

    Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 855 in its research report dated November 14, 2022.

  • Stock Market Live: Why PB Fintech gained and Paytm fell to new low | Lupin, PNB, Fino Payments in focus Nov 25, 2022 08:25 AM IST

    Stock Market Live: Why PB Fintech gained and Paytm fell to new low | Lupin, PNB, Fino Payments in focus

    European markets extend gains on Fed slowdown hopes. Stoxx600 gained 0.5%, all other key bourses in the Eurozone also ended firmly in the green. In our what’s trending segment, we do a deep dive into internet companies PB Fintech and Paytm. On the technical front, we train the spotlight on Lupin, PNB and Fino Payments Bank.

  • Reduce Lupin; target of Rs 680: ICICI Direct Nov 23, 2022 02:46 PM IST

    Reduce Lupin; target of Rs 680: ICICI Direct

    ICICI Direct recommended reduce rating on Lupin with a target price of Rs 680 in its research report dated November 11, 2022.

  • Buy Lupin; target of Rs 855: Sharekhan Nov 20, 2022 07:43 PM IST

    Buy Lupin; target of Rs 855: Sharekhan

    Sharekhan is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 855 in its research report dated November 14, 2022.

  • Neutral Lupin; target of Rs 680: Motilal Oswal Nov 16, 2022 03:49 PM IST

    Neutral Lupin; target of Rs 680: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 680 in its research report dated November 10, 2022.

  • Hold Lupin; target of Rs 650: Prabhudas Lilladher Nov 15, 2022 02:22 PM IST

    Hold Lupin; target of Rs 650: Prabhudas Lilladher

    Prabhudas Lilladher recommended hold rating on Lupin with a target price of Rs 650 in its research report dated November 11, 2022.

  • Lupin Standalone September 2022 Net Sales at Rs 2,828.96 crore, down 1.44% Y-o-Y Nov 10, 2022 02:20 PM IST

    Lupin Standalone September 2022 Net Sales at Rs 2,828.96 crore, down 1.44% Y-o-Y

  • Lupin Consolidated September 2022 Net Sales at Rs 4,145.52 crore, up 1.32% Y-o-Y Nov 10, 2022 02:04 PM IST

    Lupin Consolidated September 2022 Net Sales at Rs 4,145.52 crore, up 1.32% Y-o-Y

  • Lupin share price gains 8% after reporting Rs 129.7-crore profit in Q2 Nov 10, 2022 08:55 AM IST

    Lupin share price gains 8% after reporting Rs 129.7-crore profit in Q2

    Revenue of the company was up 1.3% at Rs 4,145.5 crore versus Rs 4,091.3 crore, YoY.

  • Lupin gets USFDA nod for generic oral contraceptive pill Nov 04, 2022 02:03 PM IST

    Lupin gets USFDA nod for generic oral contraceptive pill

    The company has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Drospirenone Tablets in 4 mg strength, the Mumbai-based drug maker said in a statement.